Priority review and breakthrough status for AZ’ acalabrutinib

2nd August 2017 Uncategorised 0

AstraZeneca and group member Acerta Pharma say acalabrutinib is being given a priority review by the US Food and Drug Administration for mantle cell lymphoma (MCL), hot on the heels of it having been assigned a breakthrough designation by the regulator.

More: Priority review and breakthrough status for AZ’ acalabrutinib
Source: News